Chelsea Carlson
Associate
Chicago
chelsea.carlson@lw.com
+1.312.777.7193
PRACTICES
- Capital Markets
- Public Company Representation
INDUSTRIES
EDUCATION
- JD, Duke University School of Law, 2021
cum laude - BA, University of Minnesota, 2018
with high distinction
LANGUAGES SPOKEN
PROFILE
Chelsea Carlson is a corporate associate in the Chicago office of Latham & Watkins.
Chelsea represents public and private issuers and financial institutions on corporate and securities matters in a range of global capital markets transactions, including initial public offerings, follow-on and secondary equity offerings, and investment grade and high-yield debt offerings. Chelsea also advises corporate clients on general corporate and securities matters, including public company reporting.
Chelsea received her JD from Duke University, where she was a staff editor on the Duke Law Journal and worked as a research assistant.
EXPERIENCE
Chelsea’s recent experience includes representing:
- The underwriters in the US$1.07 billion public offering of ordinary shares of Viking Holdings Ltd
- UL Solutions Inc. in connection with its US$1.13 billion public offering of common stock
- The initial purchasers in the US$200 million high-yield notes offering by Mercer International Inc.
- Sable Offshore Corp. in connection with its US$150 million PIPE offering
- Hyatt Hotels in multiple senior notes offerings
- Simon Property Group in multiple senior notes offerings
- The underwriters in the upsized US$1.5 billion initial public offering for Viking Holdings Ltd
- UL Solutions Inc. in its upsized US$1.08 billion initial public offering
- Reddit, Inc. in its US$748 million initial public offering
- AAR CORP. in its US$550 million senior notes offering
- The initial purchasers in multiple high-yield notes offerings by Viking Cruises Ltd
- UL Solutions Inc. in its inaugural US$300 million high-yield notes offering
- The underwriters in the US$83 million offering of common stock by SI-BONE, Inc. and certain selling stockholders
- Flame Acquisition Corp., a special purpose acquisition entity, in its business combination with Sable Offshore Corp.
- Imago BioSciences, Inc. in its US$1.35 billion take-private sale to Merck & Co., Inc.
- Cerner Corporation in its US$28 billion take-private sale to Oracle